Center for Personalized Cancer Therapy

at the University of Massachusetts Boston

Read About Us In its home in the Integrated Sciences Complex, the Center for Personalized Cancer Therapy will provide a means for undergraduate and graduate students to become the next generation of well-trained biomedical workforce talent and the future leaders of life sciences research in academia and industry.
Immunohistochemistry Expression of a protein, CXCL5, is elevated in prostate tumors. A major goal of the CPCT is to establish a monoclonal antibody core focused on the development of antibodies that successfully identify signaling molecules proteins coupled to cancer diagnosis, prognosis, and response to therapy.
The CPCT is located in the VDC The CPCT is currently housed in the Venture Development Center in Wheatley Hall and will move to the Integrated Science Complex in 2014.
Graph of CXCL5 expression in prostate tissues Expression levels of the CXCL5 protein increase from normal (benign) to primary prostate tumors (PCa) to metastatic tumors (METs), showing that CXCL5 is a marker of prostate tumor progression.

News

Support the development of individualized therapeutic choices to successfully eliminate cancer.